LAVA Therapeutics (LVTX) Reports Q4, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
March 24, 2022 6:30 AM EDTLAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022LAVA-1207 Phase 1/2a trial in mCRPC on track to report initial data in H2 2022New pipeline program: LAVA-1266, a CD123-directed Gammabody for hematological malignanciesStrong balance sheet with cash and investments of $133.2 million as of December 31, 2021
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2022 (GLOBE NEWSWIRE) --... More
